Added to YB: 2026-01-27
Pitch date: 2026-01-23
GSK [neutral]
GSK plc
+24.48%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 86.9B
Pitch Price
GBP 17.88
Price Target
N/A
Dividend
3.33%
EV/EBITDA
7.63
P/E
15.60
EV/Sales
3.08
Sector
Pharmaceuticals
Category
value
Theodosian Capital | Stocks Update 23/1/2026 - GSK – M&A
GSK (update): Acquired RAPT Therapeutics for $1.9bn to bolster food allergy pipeline (ozureprubart Phase IIb results due 2025, 17M+ US market). Pfizer exits ViiV JV, Shionogi increases to 21.7% stake. GSK trades cheaply at 9.3x 2027 consensus earnings, 3.9% yield vs peers.
Read full article (1 min)